Skip to main content

Advertisement

Table 2 Baseline clinical characteristics and TB incidence of HIV/AIDS patients who started ART from September 2007 to August 2008 at the University of Gondar Hospital

From: The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up study

Variable Total Incident TB+ Incident TB-
Female sex (n[%]) 258(64.5) 18(69.2) 240(64.2)
Age (years, mean [SD]) 34.37 ± 9.29 35.4 ± 8.8 34.3 ± 9.3
WHO HIV clinical stage (n[%])    
  I 57(14.3) 2(3.5) 55(96.5)
  II 86(21.5) 6(7.0) 80(93.0)
  III 208(52.0) 13(6.2) 195(93.8)
  IV 49(12.3) 5(10.2) 44(89.8)
CD4 count (cells/mm 3 , median [IQR]) 152(82, 203) 98(58,201.75) 153(86,203)
CD4 count (cell/mm 3 , n[%])    
  0-99 127(31.8) 13(10.4) 112(89.6)
  ≥100 170(42.5) 13(4.7) 262(95.3)
Initial ART Regimen (n[%])    
  d4T/3TC/NVP or EFV 49(12.3) 4(8.2) 45(91.8)
  AZT/3TC/NVP or EFV 189(47.3) 15(7.9) 174(92.1)
  TDF/3TC/NVP or EFV 162(40.5) 7(4.3) 155(95.7)
Functional status (n[%])    
  Working 340(85.0) 20(5.9) 320(94.1)
  Ambulatory 49(12.3) 4(8.2) 45(91.8)
  Bed ridden 11(2.8) 2(18.2) 9(81.8)
  1. d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; AZT: zidovudine; EFV: efavirenz; TDF: tenofobir; TB: tuberculosis; HIV: human immunodeficiency virus; ART: antiretroviral therapy; IQR: interquartile range; SD: standard deviation; WHO: world health organization.